EdiGene, Immunochina to develop CAR-T therapy

By The Science Advisory Board staff writers

May 27, 2020 -- EdiGene and Immunochina have announced they are collaborating on the development of allogeneic CAR-T therapy for cancer.

Both companies have experience in late-stage hematological malignancies. Though strides have been made in the use of autologous T-cell therapies, they believe allogeneic T cells could also play an important role in future treatments, according to the companies.

No other details about the partnership were provided.

If you like this content, please share it with a colleague!

Related Reading

Avectas, ONK to develop cancer cell therapy
Avectas has exclusively licensed a chimeric antigen receptor-directed natural killer cell therapy from ONK Therapeutics for the treatment of B-cell malignancies...

AGC Biologics, Faron to manufacture cancer immunotherapy
Contract development and manufacturing organization AGC Biologics has formed a cancer immunotherapy partnership with Faron Pharmaceuticals.

Trio, Ajinomoto to develop cancer therapeutic
Cancer therapeutics company Trio Pharmaceuticals and biopharmaceutical contract development and manufacturing company Ajinomoto Bio-Pharma Services have...

Kleo, Green Cross collaborate on COVID-19 NK combination therapy
Kleo Pharmaceuticals is joining forces with Green Cross LabCell of South Korea to advance testing of natural killer (NK) cell therapies as a potential...

Success of immunotherapies increased in cancer patients through co-treatment with monoclonal antibodies
A new approach provides evidence that it is possible to break down the protective wall surrounding tumor cells, therefore making immunotherapies more...